Our study suggested that APE1 combined with CD4+ T cells might be a potential predictor of outcome in patients with NSCLC, and combining immunotherapy and APE1-targeted therapy may be a promising treatment for NSCLC. The gene discussed is APEX1; the disease is non-small cell lung carcinoma.